Product Information
BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG TABLET is a generic product labeled by Granules Pharmaceuticals Inc., priced at $0.1223 per EA under NDC 70010014901. Its NADAC has been published 214 times since Aug 31, 2022.
FDA first approved this application on Dec 1, 2008. Its Orange Book therapeutic-equivalence code is AA.
BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG TABLET
Butalbital, Acetaminophen and CaffeineStrength
325; 50; 40 mg/1; mg/1; mg/1
Manufacturer
Granules Pharmaceuticals Inc.NDC
70010014901
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ACETAMINOPHEN; BUTALBITAL; CAFFEINEApproval Type
Generic (ANDA)
FDA Application
ANDA040864FDA Approved
12/1/2008
TE Code
AA
On Market Since
6/29/2022
Pharmacological Classes
Price Statistics
The NADAC for BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG TABLET has been published 214 times since Aug 31, 2022, and over the history we have for it it has declined 33.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1223 per EA |
|---|---|
| All-time high | $0.1852 (Oct 12, 2022) |
| All-time low | $0.1112 (Nov 20, 2024) |
| 52-week high | $0.1398 |
| 52-week low | $0.1218 |
| Median price | $0.1489 |
| Average price | $0.1457 |
| Largest weekly change | +35.2% (Aug 21, 2024) |
| Weeks tracked | 214 |
| Tracking since | Aug 31, 2022 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Granules Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Butalbital, Acetaminophen and Caffeine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Barbiturate class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG TABLET, manufactured by Granules Pharmaceuticals Inc., is $0.1223 per EA (NDC 70010014901), effective Sep 30, 2026.
How has the price of BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG TABLET changed over time?
Over the history we have for it, the NADAC for BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG TABLET has declined 33.5%. It has been tracked across 214 weekly CMS publications since Aug 31, 2022.
What are the highest and lowest recorded NADAC prices for BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG TABLET?
Since Aug 31, 2022, the NADAC for BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG TABLET has ranged from a low of $0.1112 (Nov 20, 2024) to a high of $0.1852 (Oct 12, 2022), with a median of $0.1489 per EA.
Are there cheaper alternatives to BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG TABLET?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG TABLET?
BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG TABLET (NDC 70010014901) is labeled by Granules Pharmaceuticals Inc., and CMS classifies it as a generic product.